Introduction
============

Chronic obstructive pulmonary disease (COPD) is a debilitating multicomponent respiratory condition primarily affecting the airway and lung parenchyma but also inducing a variety of extrapulmonary consequences, such as systemic inflammation, nutritional abnormalities, weight loss, skeletal muscle dysfunction and additional organ effects ([@b12-copd-3-683]). The high burden of COPD resulting from cough, sputum production and shortness of breath, is further contributed to by systemic effects, leading to a pronounced deterioration in health status and a diminished quality of life. It has been largely recognized that COPD is a public health problem worldwide and a major cause of chronic morbidity and mortality ([@b10-copd-3-683]; [@b29-copd-3-683]; [@b25-copd-3-683]). COPD is a highly prevalent disease, and it is estimated that 7%--10% of the adult population may be affected ([@b33-copd-3-683]; [@b18-copd-3-683], [@b19-copd-3-683]). In spite of antismoking campaigns, the prevalence and mortality rates of COPD continue to rise every year. It has been shown that COPD is the most rapidly increasing cause of death in individuals older than 65 years of age, which represents the most rapidly growing segment of the population in developed countries. Disability from COPD is expected to rise by 2020 with aging of the population and the increase in disease prevalence ([@b39-copd-3-683]).

Health-related quality of life (HRQL) in COPD patients has received an increasing interest over the past decade. An impaired health status is a risk factor for frequent exacerbations and hospital admissions ([@b27-copd-3-683]). Previous studies using both generic and disease-specific instruments for measuring HRQL in COPD patients ([@b24-copd-3-683]) have shown relationships between HRQL and disease severity, respiratory symptoms, gender, comorbidity, body weight, upper airway symptoms, and psychological status ([@b17-copd-3-683]; [@b40-copd-3-683]; [@b30-copd-3-683]; [@b21-copd-3-683]; [@b22-copd-3-683]; [@b34-copd-3-683]; [@b11-copd-3-683]). In a recent study carried out in Spain, determinants of HRQL in patients with COPD followed in primary care included sex, forced expiratory volume in one second (FEV~1~), use of oxygen therapy, and number of visits to emergency rooms and hospital admissions ([@b9-copd-3-683]).

In order to provide further information on HRQL in patients with COPD, a multicenter cross-sectional study was designed, the primary objectives of which were to collect information on HRQL in a large sample of outpatients with COPD visited by family physicians and pneumologists in actual conditions of the daily practice and to determine whether there were differences in HRQL according to age, gender, and severity of COPD. Secondary objectives included to assess the correlation between quality of life perceived by COPD patients and functional status (FEV~1~) and level of dyspnea, and to determine health care resources consumption.

Methods
=======

Study design
------------

The *VICE* Study (Spanish acronym of *Living with Chronic Obstructive Pulmonary Disease*) was a 2-month (April--May 2004) cross-sectional survey of the first five consecutive patients with COPD in the outpatient setting seen by general practitioners in primary care centers and pneumologists in the outpatients clinics of the Services of Pneumology of acute care hospitals from all over Spain. A sample of 2300 general practitioners and 200 pneumologists were recruited using a stratified random sample drawn from the list of registered physicians in all autonomous communities. Physicians were eligible for inclusion if they were actively practicing in Spain, reported spending at least 50% of their time in direct patient care and had a primary specialty in family practice or pneumology. Physicians participated voluntarily in the study and did not receive any payment.

The study protocol was approved by the Ethics Committee of hospital Gregorio Marañón, Madrid (Spain), and written informed consent was obtained from all participants.

Patients
--------

Patients of both sexes, aged 40 years or older, with a previous diagnosis of COPD (confirmed by history and spirometry) were eligible provided that the reason of consultation was related to his/her pulmonary condition. The diagnosis of the disease was performed according to the criteria of the Spanish Society of Pneumology and Chest Surgery (SEPAR) based on the demonstration, through a forced spirometry, of a FEV~1~ below 80% of the reference value and a FEV~1~/forced vital capacity (FVC) ratio below 0.7 after the bronchodilation test. The severity of COPD was graded according to the FEV~1~ value: mild (FEV~1~ 60%--80% of the reference value), moderate (FEV~1~ 40%--59% of the reference value) and severe (FEV~1~ \< 40% of the reference value) following SEPAR criteria ([@b4-copd-3-683]), which are based on the guidelines of the British Thoracic Society ([@b6-copd-3-683]). Spirometric measurements at the time of the study were not performed.

Patients with an acute worsening of their COPD in the previous month were excluded as were those suffering from any physical and/or psychiatric disease precluding to complete the HRQL questionnaire. Patients with more than 80% of missing data for the study variables in their medical records were also excluded.

Data collection
---------------

Interviews were carried out by the participating physician during the course of the patient's consultation in routine daily practice. All data were collected in a single visit using a questionnaire in which the following variables were recorded: age; sex; height; weight; smoking habit (current smoker, never smoker, ex-smoker); year of COPD diagnosis; data of the last spirometric measurement and FEV~1~ and FEV~1~/FVC values; severity of COPD; current COPD therapy including nonpharmacological management (smoking cessation counseling, stop smoking treatment, oxygen therapy, rehabilitation, others) and pharmacological treatment (short-acting β~2~-agonists, long-acting β~2~-agonists, short-acting anticholinergics, long-acting anticholinergics, inhaled steroids, oral steroids, a fixed combination of anticholinergics and short-acting β~2~-agonists, a fixed combination of long-acting β~2~-agonists and inhaled steroids, antibiotics, others); disability; and health resources utilization in the previous 12 months (number of outpatient visits to either the primary care physician and the pneumologist, emergency department visits, hospitalizations, and days on sick leave).

Disability was classified according to the Medical Research Council (MRS) dyspnea scale ([@b5-copd-3-683]). The MRC dyspnea scale concerns perceived breathlessness and consists of five degrees: 1, "shortness of breath with strenuous exercise"; 2, "shortness of breath when hurrying"; 3, "walking slower than people of the same age on the level ground or stop for breath while walking at own pace on the level ground"; 4, "needing to stop after 100 yards on the level ground"; 5, "too breathless to leave the house". A Spanish translation of MRC dyspnea scale was administered to the subjects ([@b15-copd-3-683]).

Health status
-------------

All patients were administered the Short Form 12 Health Survey Questionnaire (SF-12), an abbreviated version of the SF-36 health questionnaire that contains 12 items ([@b38-copd-3-683]). These 12 items explain more than 90% of the variance of the physical and mental component scales of the SF-36. From them two scores can be calculated, the physical (PCS-12) and the mental (PCS-12) component summary, using a value of 50 with a standard deviation of 10 as reference population. In this study, the general Spanish adult population has been used as reference ([@b1-copd-3-683]; [@b36-copd-3-683]). Scores range from 0 to 100, with higher scores representing better HRQL. A score \>60 has been regarded as high HRQL, 40--60 as normal HRQL, and \<40 as impaired (low) HRQL. A translated version of the questionnaire validated for Spain has been used ([@b2-copd-3-683]).

Statistical analysis
--------------------

In order to detect a clinically relevant differences of 5 points in the mean PCS-12 and MCS-12 scores among the subgroups of men and women stratified by the three severity levels of COPD with a statistical power of 95% and a level of statistical significance (alpha) of 0.05, using a two-tailed Student's *t* test for the comparison of two groups (considering a standard deviation of 12 for the mean SF-12 scores of each group), a total number of patients required in each stratum was 165. According to data of the IBERPOC study ([@b32-copd-3-683]; [@b37-copd-3-683]), women showed the lowest prevalence of COPD (22%) with the subset of women with severe disease accounting for 1.653% of the total number of patients with COPD. Therefore, the total number of patients required was 9981 (165/0.01653). This number was increased to 12,477 assuming losses of patients due to nonevaluable cases of 20%.

The Statistical Package for the Social Sciences (version 12.0; SPSS Inc., Chicago, IL) was used for the analysis of data. Double data entry was carried out with a subsequent validation to guarantee the quality and consistency of the data. Continuous variables are expressed as mean and standard deviation (SD) or median and ranges (25th--75th percentiles). Qualitative variables are described as frequency and percentages. Confidence intervals (CIs) were calculated at the 95% level. Differences of HRQL in the subgroups of patients according to gender and severity of COPD were analyzed with the paired Student's *t* test. The Spearman's rank-order correlation coefficient (ρ) was calculated to assess the relationship between HRQL and FEV~1~ and level of dyspnea. The chi-square (χ^2^) test was used to assess differences in health resources utilization among the study groups. Statistical significance was set at *P* ≤ 0.05.

Results
=======

The number of physicians participating in the study was 2144 (general practitioners, n = 1826; pneumologists, n = 240), which enabled a recruitment total of 10,782 patients. However, 1377 patients (12.8%) were excluded due to missing data in the patient's medical history (n = 831) and lack of fulfillment of the selection criteria (n = 546).

The study population included 9405 patients (79.7% men, 20.3% women) with a mean (±SD) age of 67.8 ± 9.8 years. Sociodemographic and clinical characteristics of the patients are shown in [Table 1](#t1-copd-3-683){ref-type="table"}. Salient features were as follows: 69% of patients were found in the 60--79 year stratum, 77% had a body mass index (BMI) ≥ 25 kg/m^2^, 61% were ex-smokers (median of 10 years since smoking cessation) and 22.6% were current smokers (median pack-years 40) and had been smoking for a mean of 36.7 ± 13.6 years. Patients had a long-standing COPD, with a mean time since diagnosis of 10 years.

With regard to the last spirometric measurement, the mean FEV~1~ value was 55.1 ± 14.3%. The severity of disease was mild in 33.8% of cases, moderate in 49.3% and severe in 16.8%. There were differences in COPD severity according to gender, with significantly higher percentages of men compared to women with moderate (50.4% vs 45.4%) and severe (18.0% vs 10.7%) disease (*P* \< 0.001). 40.8% of patients aged 40--50 years suffered from moderate or severe COPD as opposed to 76.1% of patients of 80 years of age or older (*P* \< 0.001). Most patients (46%) had a moderate degree of dyspnea (MRC category 2). However, 14.5% of men showed a moderately severe degree of dyspnea (MRC categories 4 and 5) compared with 13.7% of women. The degree of dyspnea also increased with age, with 3.4% of patients aged 40--50 years in the MRC categories 4 and 5 compared with 29.2% of patients aged 80 years or older (*P* \< 0.001).

The mean PCS-12 and MCS-12 scores were 36.8 ± 10.4 and 47.2 ± 11.2, respectively. General health and physical functioning domains were those with the lowest scores, whereas role emotional and social functioning domains were those with the highest scores ([Table 2](#t2-copd-3-683){ref-type="table"}). According to results of the SF-12 questionnaire, HRQL was graded as normal (40--60 points) by 61% of patients and low (\<40 points) by 39% of patients. However, a higher percentage of patients scored less than 40 points in the physical health domain compared with the mental health domain (60.2% vs 25.7%) ([Table 2](#t2-copd-3-683){ref-type="table"}). As compared to the reference population, patients with COPD had a reduction of HRQL, with a mean of −1.32 ± 1.04 for PCS-12 and −0.28 ± 1.12 for MCS-12.

When HRQL in men and women was compared, there were no significant differences in the mean PCS-12 scores (36.9 ± 10.4 vs 36.5 ± 10.3) but the mean MCS-12 scores were significantly higher in men (47.9 ± 10.9) than in women (44.1 ± 11.8) (*P* \< 0.001). Scores for the different domains of PCS-12 and MSC-12 according to gender are shown in [Figure 1](#f1-copd-3-683){ref-type="fig"}. As compared with the reference population, the mean reduction of HRQL for the mental domain was significantly higher in women (−0.59 ± 1.18) than in men (−0.20 ± 1.09) (*P* \< 0.001).

As shown in [Table 3](#t3-copd-3-683){ref-type="table"}, the physical domain was scored \<40 points by a significantly higher percentage of patients compared with the mental domain for all age strata. On the other hand, the percentage of patients considering that their HRQL in the physical domain was normal or high was also significantly lower than for the mental domain. Patients older than 60 years of age rated HRQL worse than patients in the 40--59 year age group.

In relation to COPD severity, a significantly higher percentage of patients with mild disease rated HRQL as normal compared with patients with severe disease (physical domain 61.3% vs 18.5%; mental domain 75.9% vs 53.5%; *P* \< 0.001) ([Table 3](#t3-copd-3-683){ref-type="table"}). The mean PCS-12 scores were 42.4 ± 9.5 in patients with mild disease, 35.2 ± 9.5 in those with moderate COPD and 30.6 ± 9.5 in those with severe disease (P \< 0.001); the corresponding figures for the mean MCS-12 scores were 49.1 ± 10.1, 47.0 ± 11.1 and 43.9 ± 13.0 in the groups of mild, moderate and severe COPD, respectively. There were statistically significant differences according to severity of disease in the mean scores of all domains of the PCS-12 and MCS-12 scales ([Figure 2](#f2-copd-3-683){ref-type="fig"}). Moreover, patients with severe COPD showed a significantly higher reduction of HRQL for both the physical (−1.94 ± 0.95) and mental domains (−0.61 ± 1.30) than patients with moderate or mild COPD as compared with the reference population.

HRQL correlated significantly with FEV~1~ in both PCS-12 (ρ = 0.313, *P* \< 0.001) and MCS-12 (ρ = 0.101, *P* \< 0.001) scales. As expected, an inverse significant correlation between HRQL and degree of dyspnea in the PCS-12 (ρ = −0.599, *P* \< 0.001) and the MCS-12 (ρ = −0.237, *P* \< 0.001) scales was observed.

In relation to utilization of health resources, patients with severe COPD had more visits to the primary care center in the previous 12 months than those with mild to moderate COPD (5.8, 4.6 and 3.2, respectively, *P* \< 0.001). They were also in the emergency department more often (2.5, 1.6 and 0.9, respectively, *P* \< 0.001). Patients with severe COPD had longer hospital stays (16.7 days) when compared to those with moderate (10.9 days) or mild disease (8.8 days) (*P* \< 0.001) as well as a more days on sick leave (51.2, 29.4 and 18.9, respectively, *P* \< 0.001).

Details of nonpharmacological and pharmacological treatment according to HRQL and severity of COPD are summarized in [Table 4](#t4-copd-3-683){ref-type="table"}. Anti-smoking treatment was recorded ino nly 4% of patients, and even in a lower percentage of patients (3.6%) with severe COPD. More than 80% of patients were receiving pharmacological treatment (bronchodilators in 73.7%, fixed combinations in 57.5% and steroids in 19.8%). Long-acting β~2~-agonists were given to 42% of patients. When patients were stratified according to normal or low HRQL, a significantly higher percentage of patients with low HRQL received any modality of pharmacological treatment except for long-acting anticholinergics. In addition, a significantly higher percentage of patients with severe COPD received any of medication as compared with those with mild and moderate severity of disease.

Discussion
==========

The use of HRQL measures in COPD has currently achieved widespread acceptance ([@b13-copd-3-683]). However, HRQL measures have shown an inconsistent relationship with clinical and functional components of the disease. The objective of this study was to assess HRQL in a large population of COPD patients during the patients' routine care in the outpatient setting. A generic quality of life questionnaire, the SF-12 that enables to calculate the physical well-being and the mental-well being components of HRQL was administered to all patients. This instrument has been shown to be a valid evaluation tool with excellent measurement properties in patients with chronic respiratory conditions, such as COPD and asthma (Katz et al 2000; [@b16-copd-3-683]; [@b26-copd-3-683], [@b28-copd-3-683]).

In general, most patients perceived that their HRQL was not impaired by COPD, although the physical health domain was rated poorly than the mental health domain, with general health, physical functioning, role physical and vitality showing lowers scores than the domains of mental health, emotional role, social functioning and bodily pain. Lower scores for the PCS-12 component than for the MSC-12 component in patients with COPD have been also reported by others ([@b34-copd-3-683];[@b9-copd-3-683]).

In agreement with previous reports ([@b30-copd-3-683]; [@b11-copd-3-683]; [@b9-copd-3-683]), the present findings confirm the effect of age, gender and stage of disease on HRQL in patients with COPD. It has been shown that COPD is a main cause of severe deterioration of quality of life in elderly subjects and that the degree of this impairment mainly depends on the severity of airway obstruction ([@b30-copd-3-683]). In our study, patients older than 60 years of age, particularly those in the 70--79-year-old group, perceived that their HRQL was more affected by COPD than younger patients. However, in the age stratum of very old patients (≥80 years), a lower percentage of subjects considered that their quality of life for the physical and mental health domains was low as compared with patients aged 70 to 79 years. This observation may be related to that fact that the oldest elderly population tend to restrict their own daily activities and expectations.

Compared with men, women had worse scores in all domains of mental health and in the role of physical and bodily pain of the physical health domain. Taking into account that a significantly percentage of men had moderate and severe COPD, this observation is clinically relevant as indicating that women with COPD develop symptoms influencing HRQL with less degree of obstruction than men. Unfortunately, a better characterization of our female population is not feasible given that other factors, such as socioeconomic status, education level, working status or co-morbidity were not evaluated. However, our results are in-line with those reported by [@b11-copd-3-683] in a FEV~1~-matched case series study of 73 consecutive women and 73 men. These authors speculate that the factors affecting HRQL differ by gender at least in early stages of the disease and that the perceived expression of the disease is different between genders. In the study of [@b3-copd-3-683] in which differences in health status according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria was evaluated, female sex was also associated with a greater impact of COPD on the health status.

In our study, like others ([@b14-copd-3-683]; [@b17-copd-3-683]) disease severity (based on FEV~1~) influenced significantly HRQL among subjects with COPD. Therefore, staging criteria for COPD based on percentage of predicted FEV~1~ separated groups of patients with varying degrees of impairment in HRQL. Contrary to expectations, even patients with mild disease showed substantially compromised HRQL. Additionally, the importance of dyspnea causing patients with COPD to reduce their activities of daily living ([@b31-copd-3-683]) is also demonstrated in our study, with dyspnea showing a stronger correlation with HRQL than FEV~1~.

A remarkable finding was that 22.6% of COPD patients were current smokers but only 4% of the total population was receiving smoking cessation treatment. In a survey of 11,973 COPD patients carried out in Spain, 35% of them continued smoking ([@b35-copd-3-683]). Our patients had been smoking for about 40 years and the median pack-years was 40. Effective intervention strategies directed to quit smoking in COPD patients are mandatory. With regard to pharmacological treatment, bronchodilators, fixed combinations and steroids were the most frequently used medications. Anticholinergics were used by 58.5% of the patients followed by β~2~-agonists (50%), theophylline (21.4%), inhaled steroids (15.9%) and oral steroids (7.5%). High dose inhaled corticosteroids in patients with moderate to severe chronic obstructive pulmonary disease has been associated with a reduced rate of decline in health status ([@b8-copd-3-683]). Finally, we also found a strong relationship between health-care resource utilization and severity of disease ([@b20-copd-3-683]).

Our study had some limitations. A generic questionnaire was used to measure HRQL, which is less sensitive than the specific tools. The cross-sectional design of the study limits our ability to describe how progression of disease stage relates to changes in HRQL. Patients were recruited from those visited in the outpatient setting, mostly in primary care centers, and therefore may not represent the COPD population at large. It should be noted that 16% of our population were never smokers. These patients were not excluded because the objective of the study was to assess HRQL in outpatients with COPD attended by family physicians and pneumologists in actual conditions of the daily practice. However, a diagnosis other than COPD cannot be excluded. In a recent multicenter study carried out in 9425 subjects with COPD recruited at 12 different sites worldwide, the percentage of never smokers varied between 3.1% and 9.4% in men and between 2.9% and 11.2% in women ([@b7-copd-3-683]). On the other hand, other factors that may affect HRQL (eg, co-morbidity) were not evaluated. However, the large sample size strengths the findings of our study.

In summary, this study shows the influence of female gender, older age and moderate-to-severe of airflow limitation on HRQL, particularly on the physical component of the SF-12 instrument, in patients with COPD attended in the outpatient setting in daily practice conditions.
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###### 

Sociodemographic and clinical characteristics of patients

  Characteristic                          Number (%)    Mean ± SD (range)[\*](#tfn2-copd-3-683){ref-type="table-fn"}
  --------------------------------------- ------------- --------------------------------------------------------------
  Total no of patients                    9405          
  Age, years (n = 9095)                                 67.8 ± 9.8 (61--75)
  Age groups (n = 8744)                                 
  40--49 years                            405 (4.6)     
  50--59 years                            1324 (15.1)   
  60--69 years                            2932 (33.5)   
  70--79 years                            3120 (35.7)   
  ≥80 years                               963 (11.1)    
  Sex (n = 8808)                                        
  Men                                     7022 (79.7)   
  Women                                   1786 (20.3)   
  Height cm mean (SD) (n = 9124)                        166.1 ± 7.7 (161--171)
  Weight kg. mean (SD) (n = 9017)                       76.3 ± 12.1 (69--84)
  Body mass index (BMI) (n = 8930)                      
  \<25 kg/m^2^                            2090 (23.4)   
  25--29 kg/m^2^                          4677 (52.4)   
  30--34 kg/m^2^                          1735 (19.4)   
  35--39 kg/m^2^                          341 (3.8)     
  ≥40 kg/m^2^                             87 (1.0)      
  Smoking (n = 9347)                                    
  Never                                   1500 (16.0)   
  Ex-smoker                               5737 (61.4)   
  Current smoker                          2110 (22.6)   
  Years since COPD diagnosis (n = 7157)                 9.7 ± 7.9
  FEV~1~% predicted (n = 7214)                          55.1 ± 14.3 (45--66)
  FEV~1~/FVC % (n = 5850)                               61.6 ± 14.4 (52--70)
  Severity of COPD (n = 9049)                           
  Mild                                    3062 (33.8)   
  Moderate                                4464 (49.3)   
  Severe                                  1523 (16.8)   
  MRC dyspnea scale (n = 9211)                          
  1                                       1353 (14.7)   
  2                                       4237 (46.0)   
  3                                       2293 (24.9)   
  4                                       1018 (11.1)   
  5                                       310 (3.4)     

Abbreviations: COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; MRC, Medical Research Council; SD, standard deviation.

**Note:** 25th--75th percentile.

###### 

Quality of life in patients with COPD

  SF-12 questionnaire                   Mean ± SD     No patients (%)
  ------------------------------------- ------------- -----------------
  Physical component summary (PCS-12)   36.8 ± 10.4   
  Mental component summary (MCS-12)     47.2 ± 11.2   
  SF-12 scales                                        
  Physical functioning                  38.6 ± 32.1   
  Role physical                         44.8 ± 46.1   
  Bodily pain                           64.3 ± 29.4   
  General health                        30.9 ± 19.5   
  Vitality                              43.4 ± 26.7   
  Social functioning                    65.9 ± 27.1   
  Emotional role                        73.1 ± 41.5   
  Mental health                         63.1 ± 20.8   
  Physical domain (n = 9,405)                         
  High (\>60 points)                                  26 (0.3)
  Normal (40--60 points)                              3714 (39.5)
  Low (\<40 points)                                   5665 (60.2)
  Mental domain (n = 9,405)                           
  High (\>60 points)                                  613 (6.5)
  Normal (40--60 points)                              6373 (67.8)
  Low (\<40 points)                                   2419 (25.7)

**Abbreviations:** COPD, chronic obstructive pulmonary disease; SD, standard deviation; SF-12, Medical Outcomes Study Short Form 12 Health Survey Questionnaire.

###### 

Differences in HRQL according to age and severity of COPD

  Variable              Physical domain   Mental domain                                           
  --------------------- ----------------- --------------- ------------- ----------- ------------- -------------
  Age groups, years                                                                               
  40--49 (n = 2193)     10 (0.5)          1112 (50.7)     1071 (48.8)   145 (6.6)   1546 (70.5)   502 (22.9)
  50--59 (n = 1990)     3 (0.2)           742 (37.3)      1245 (62.6)   131 (6.6)   1384 (69.5)   475 (23.9)
  60--69 (n = 1382)     2 (0.1)           439 (31.8)      941 (68.1)    80 (5.8)    914 (66.1)    388 (28.1)
  70--79 (n = 519)      2 (0.4)           139 (26.8)      378 (72.8)    25 (4.8)    330 (63.6)    164 (31.6)
  ≥80 (n = 1073)        2 (0.2)           344 (32.1)      727 (67.8)    79 (7.4)    678 (63.2)    316 (25.9)
  COPD severity                                                                                   
  Mild (n = 3062)       16 (0.5)          1876 (61.3)     1170 (38.2)   179 (5.8)   2323 (75.9)   560 (18.3)
  Moderate (n = 4464)   9 (0.2)           1425 (31.9)     3030 (67.9)   284 (6.4)   3000 (67.2)   1180 (26.4)
  Severe (n = 1523)     1 (0.1)           282 (18.5)      1240 (81.4)   130 (8.5)   815 (53.5)    578 (38.0)

**Abbreviations:** COPD, chronic obstructive pulmonary disease; HRQOL, health-related quality of life.

**Note:** Percentages in parenthesis.

###### 

Management of patients with COPD: nonpharmacological and pharmacological treatment in the previous 12 months

  Management                                        Total population (n = 9405)   Health-related quality of life   Severity of COPD                                                     
  ------------------------------------------------- ----------------------------- -------------------------------- ------------------ ------- ------------- ------------- ------------- -------
  Nonpharmacological therapy                        4479 (47.6)                   2568 (44.7)                      1911 (52.2)        0.001   1313 (42.9)   2134 (47.8)   892 (58.6)    0.001
  Smoking cessation counseling                      2263 (24.1)                   1450 (25.2)                      813 (22.2)         0.001   811 (26.5)    1032 (23.1)   355 (23.3)    0.002
  Stop smoking treatment                            385 (4.1)                     239 (4.2)                        146 (4.0)          0.689   136 (4.4)     184 (4.1)     55 (3.6)      0.411
  Oxygen therapy                                    813 (8.6)                     235 (4.1)                        578 (15.8)         0.001   47 (1.5)      305 (6.8)     434 (28.5)    0.001
  Rehabilitation                                    947 (10.1)                    457 (8.0)                        490 (13.4)         0.001   194 (6.3)     500 (11.2)    233 (15.3)    0.001
  Pharmacological treatment                         7980 (84.8)                   4727 (82.3)                      3253 (88.9)        0.001   2416 (78.9)   3872 (86.7)   1391 (91.3)   0.001
  Bronchodilators                                   6935 (73.7)                   4176 (72.7)                      2759 (75.4)        0.003   2123 (69.3)   3319 (74.4)   1232 (80.9)   0.001
  Short-acting β~2~-agonists                        2539 (27.0)                   1449 (25.2)                      1090 (29.8)        0.001   747 (24.4)    1181 (26.5)   510 (33.5)    0.001
  Long-acting β~2~-agonists                         2167 (23.0)                   1283 (22.3)                      884 (24.2)         0.038   589 (19.2)    1059 (23.7)   424 (27.8)    0.001
  Short-acting anticholinergics                     1552 (16.5)                   900 (15.7)                       652 (17.8)         0.005   414 (13.5)    765 (17.1)    316 (20.7)    0.001
  Long-acting anticholinergics                      3953 (42.0)                   2408 (41.9)                      1545 (42.2)        0.747   1154 (37.7)   1951 (43.7)   710 (46.6)    0.001
  Fixed combinations                                5410 (57.5)                   3176 (55.3)                      2234 (61.1)        0.001   1585 (51.8)   2657 (59.5)   986 (64.7)    0.001
  Anticholinergics and short-acting β~2~-agonists   687 (7.3)                     395 (6.9)                        292 (8.0)          0.043   197 (6.4)     332 (7.4)     134 (8.8)     0.014
  Inhaled steroids and long-acting β~2~-agonists    5155 (54.8)                   3022 (52.6)                      2133 (58.3)        0.001   1510 (49.3)   2525 (56.6)   950 (62.4)    0.001
  Steroids                                          1865 (19.8)                   899 (15.6)                       966 (26.4)         0.001   359 (11.7)    949 (21.3)    479 (31.5)    0.001
  Oral                                              701 (7.5)                     226 (3.9)                        465 (13.0)         0.001   99 (3.2)      318 (7.1)     251 (16.5)    0.001
  Inhaled                                           1492 (15.9)                   773 (13.5)                       719 (19.7)         0.001   304 (9.9)     775 (176.4)   351 (23.0)    0.001
  Antibiotics                                       4671 (49.7)                   2752 (47.9)                      1919 (52.5)        0.001   1462 (47.7)   2210 (49.5)   807 (53.0)    0.003

**Abbreviations:** COPD, chronic obstructive pulmonary disease.

**Note:** Percentages in parenthesis.
